NCT00795730已完成1 期
An Ascending Multiple Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of NSA-789 Administered Orally to Healthy Subjects and Subjects With Alzheimer's Disease
Wyeth is now a wholly owned subsidiary of Pfizer0 个研究点目标入组 24 人开始时间: 2009年1月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 24
- 主要终点
- Adverse event monitoring as specific tests that will be done to monitor safety (ECGs, certain laboratory tests, vital signs) and tolerability
研究概览
简要总结
This is a multiple dose study of NSA-789, the purpose of which is to assess the safety and tolerability in healthy subjects and subjects with Alzheimer's Disease
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
placebo
Placebo Comparator
干预措施: placebo (Other)
NSA-789
Experimental
干预措施: NSA-789 (Drug)
结局指标
主要结局
Adverse event monitoring as specific tests that will be done to monitor safety (ECGs, certain laboratory tests, vital signs) and tolerability
时间窗: 6 months
次要结局
- Pharmacokinetic and pharmcodynamic parameters(6 months)
研究者
相似试验
撤回
1 期
Study Evaluating the Effects of Multiple Doses of NSA-789 in Subjects With Schizophrenia or Schizoaffective DisorderSchizophreniaNCT00892021Wyeth is now a wholly owned subsidiary of Pfizer
终止
1 期
Study Evaluating Multiple Ascending Dose in Schizophrenia PatientsHealthyNCT00620568Wyeth is now a wholly owned subsidiary of Pfizer32
已完成
1 期
Study to Evaluate Multiple Doses of ERB-041 in Healthy, Female Japanese SubjectsHealthyNCT00434187Wyeth is now a wholly owned subsidiary of Pfizer24
已完成
1 期
A Study of MK-8189 in Participants With Schizophrenia (MK-8189-014)SchizophreniaNCT05406440Merck Sharp & Dohme LLC53
已完成
1 期
Study Evaluating HKI-272 in TumorsBreast NeoplasmsNCT00146172Puma Biotechnology, Inc.73